Abstract library

13 results for "Arsenic".
#957 Outcome Predictors of Gastrinomas: The Role of ENETS Staging, Grading and Interdisciplinary Treatment
Introduction: Gastrinomas are rare neuroendocrine neoplasias (NEN) presenting with Zollinger‐Ellison‐syndrome (ZES).
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Tischer E, Pascher A, ...
#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment
Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Lisa-Marie Dilz
#1151 Gastric Neuroendocrine Neoplasias-Outcome Predictors-ENETS Staging and Grading System and Treatment
Introduction: Detailed analysis to guide management decisions in gNEN is rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Gerlach U, Pascher A, ...
#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors
Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: PD Dr. Patricia Grabowski
#1202 Role of Amplifications in the PIK3/Akt/mTOR-Pathway in Neuroendocrine Tumors of the Small Intestine
Introduction: Amplifications in the PIK3/Akt/mTOR pathway can lead to increased proliferation and reduced apoptosis, resulting in the development of various cancers. Recently, amplifications of Akt1/2, PDGFRα/β and mTOR in small intestine neuroendocrine tumors (siNET) have been shown.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Maike Hoffmeister
#1347 Evaluation of the Somatostatin, CXCR4 Chemokine and Endothelin A Receptor Expression in a Large Series of Paragangliomas
Introduction: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Prof. Amelie Lupp
#1436 Up-Regulation of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase (IDO) with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia
Introduction: Data from a considerable number of malignancies demonstrate that depletion of the essential amino acid tryptophan via induction of the immuno-regulatory enzyme Indoleamine-2,3-dioxygenase (IDO) serves as an important tumour escape strategy and is of prognostical importance.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Pape U F, Fusch G, Jann H, ...
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)
Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: PD Dr. Patricia Grabowski
#1539 Slit-Robo Signaling Links to Ras Activity to Suppress Metastasis and Is Associated with Time-to-Progression in Pancreatic Neuroendocrine Tumors
Introduction: mRNA signatures of distinct metastatic phenotypes of pancreatic NETs (pNETs) exhibit differences in several components of the Slit-Robo axon guidance system.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. med. Christian Fischer
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.